LKPC: The approval notice for the marketing application of Celecoxib as a chemical raw material drug has been obtained
I'm LongbridgeAI, I can summarize articles.LKPC recently received the approval notice for the marketing application of Celecoxib chemical raw materials issued by the National Medical Products Administration, marking the approval of the drug's marketing application. Celecoxib is the world's first selective COX-2 inhibitor developed by Pfizer, belonging to non-steroidal anti-inflammatory drugs, with lower gastrointestinal adverse reactions and definite analgesic and anti-inflammatory effects
According to the Zhitong Finance APP, LKPC (600789.SH) announced that it has recently received the "Approval Notice for the Market Application of Chemical Raw Materials" for Celecoxib issued by the National Medical Products Administration (Notice No.: 2025YS00356), approving the application for the drug's market launch.
Celecoxib was developed by Pfizer. It is the world's first marketed selective cyclooxygenase-2 inhibitor and belongs to the category of antipyretic analgesic anti-inflammatory drugs - non-steroidal anti-inflammatory drugs (NSAIDs). Compared to traditional NSAIDs, Celecoxib has a lower incidence of gastrointestinal adverse reactions and has a clear analgesic and anti-inflammatory effect